TG Therapeutics Inc.(TGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TGTX TG Therapeutics Inc.

美国独立日休市 07-02 16:00:00 EDT

53.31

-0.21

-0.39%

盘后53.35

+0.04+0.08%

19:49 EDT

最高53.77	最低51.15	成交量307.64万
今开53.52	昨收53.52	日振幅4.90%
总市值81.61亿	流通市值77.83亿	总股本1.53亿
成交额1.61亿	换手率2.11%	流通股本1.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TGTX","market":"US","secType":"STK","nameCN":"TG Therapeutics Inc.","latestPrice":53.31,"timestamp":1783022400000,"preClose":53.52,"halted":0,"volume":3076369,"hourTrading":{"tag":"盘后","latestPrice":53.35,"preClose":53.31,"latestTime":"19:49 EDT","volume":60994,"amount":3251304.7541,"timestamp":1783036159858,"change":0.04,"changeRate":0.00075,"amplitude":0.025324},"delay":0,"changeRate":-0.003923766816143513,"floatShares":146000000,"shares":153093879,"eps":2.870779,"marketStatus":"美国独立日休市","change":-0.21,"latestTime":"07-02 16:00:00 EDT","open":53.52,"high":53.77,"low":51.15,"amount":161237606.06254,"amplitude":0.048954,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.870779,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1128657600000,"exchange":"NASDAQ","adjPreClose":53.52,"preHourTrading":{"tag":"盘前","latestPrice":53.44,"preClose":53.52,"latestTime":"09:28 EDT","volume":3917,"amount":210289.844235,"timestamp":1782998880149,"change":-0.08,"changeRate":-0.001495,"amplitude":0.056594},"postHourTrading":{"tag":"盘后","latestPrice":53.35,"preClose":53.31,"latestTime":"19:49 EDT","volume":60994,"amount":3251304.7541,"timestamp":1783036159858,"change":0.04,"changeRate":0.00075,"amplitude":0.025324},"volumeRatio":0.950083897548924,"impliedVol":0.5831,"impliedVolPercentile":0.4502},"requestUrl":"/m/hq/s/TGTX","defaultTab":"news","newsList":[{"id":"1193128094","title":"异动解读｜TG Therapeutics盘中上涨6.88%，报56.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193128094","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193128094?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:50","pubTimestamp":1782136231,"startTime":"0","endTime":"0","summary":"6月22日，TG Therapeutics盘中上涨6.88%，报56.51美元/股，成交额1762.9万美元。TG Therapeutics所在的生物科技行业中，个股中，Apogee Therapeutics涨46.82%，艾伯维公司涨4.75%，吉利德科学涨0.01%，再生元制药公司跌0.94%，Moderna跌3.31%。TG Therapeutics是一家商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的收购、开发和商业化，其产品BRIUMVI已获美国、欧盟和英国批准用于治疗复发性多发性硬化症成人患者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115330337","title":"TG Therapeutics 启动 Briumvi 作为重症肌无力患者 Efgartigimod 诱导后维持治疗的二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1115330337","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115330337?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:33","pubTimestamp":1781004808,"startTime":"0","endTime":"0","summary":"TG Therapeutics 公司宣布，已启动一项二期临床试验，旨在评估其药物 Briumvi（通用名：ublituximab）作为维持疗法，用于治疗那些在完成 Efgartigimod 诱导期后的重症肌无力（Mg）患者。\n这项研究将探索 Briumvi 在维持疾病缓解方面的潜力，为重症肌无力患者提供一种新的、可能更便捷的长期治疗方案。试验设计将重点关注药物的安全性、耐受性以及维持临床疗效的能力。此举标志着 TG Therapeutics 在拓展其核心产品 Briumvi 适应症方面迈出了重要一步，特别是在自身免疫性疾病治疗领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","TGTX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100402307","title":"TG Therapeutics 皮下注射Briumvi耐受性良好，安全性特征与静脉剂型一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1100402307","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100402307?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:31","pubTimestamp":1781004697,"startTime":"0","endTime":"0","summary":"TG Therapeutics 公司宣布，其皮下注射剂型的Briumvi（ublituximab）在一项研究中普遍耐受性良好，其安全性特征与此前已获批准的静脉注射剂型保持一致。\n这一积极数据进一步支持了Briumvi作为多发性硬化症治疗方案的潜力，并为患者提供了更便捷的给药选择。皮下注射方式有望缩短治疗时间，改善患者的治疗体验。公司将继续推进相关临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136500698","title":"TG Therapeutics公布皮下注射Briumvi治疗重症肌无力的1期试验积极顶线数据，并启动潜在注册导向的随机2期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1136500698","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136500698?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:31","pubTimestamp":1781004677,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，其皮下注射制剂Briumvi在治疗重症肌无力患者的1期临床试验中获得了积极的顶线数据。基于这些积极结果，公司已启动一项潜在的注册导向性随机2期试验，旨在进一步评估该疗法的有效性与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","TGTX","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119349695","title":"TG Therapeutics公布皮下注射Briumvi®（Ublituximab-Xiiy）一期试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1119349695","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119349695?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:30","pubTimestamp":1780486232,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，其皮下注射剂型Briumvi®（Ublituximab-Xiiy）的一期临床试验取得了积极成果。该试验旨在评估这种新给药方式的安全性、耐受性及药代动力学特征。初步数据显示，皮下注射方案展现出良好的耐受性，其药代动力学特征与已获批的静脉输注剂型一致，这为患者提供了一种潜在更便捷的治疗选择。Briumvi®是一种靶向CD20的单克隆抗体，目前已获批用于治疗复发型多发性硬化症。此次皮下制剂的积极进展，有望进一步拓展该药物的应用便利性，并可能增强其在市场竞争中的优势。公司表示，将基于这些数据与监管机构进行沟通，以确定后续的开发路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149993994","title":"TG Therapeutics公布ULTIMATE III期试验在初治复发型多发性硬化症患者中的事后分析数据，发表于《免疫学前沿》","url":"https://stock-news.laohu8.com/highlight/detail?id=1149993994","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149993994?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:31","pubTimestamp":1780313497,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，其针对初治复发型多发性硬化症（RMS）患者开展的ULTIMATE I和II期3期试验的事后分析数据，已在《免疫学前沿》期刊上发表。该数据的发布为评估相关疗法在特定患者群体中的表现提供了进一步的深入见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191996105","title":"TG Therapeutics次要终点与既往研究一致；未观察到新的安全性信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1191996105","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191996105?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:34","pubTimestamp":1779881663,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc. 宣布，其临床研究的次要终点数据与公司过往的研究结果保持一致。在整个试验过程中，研究人员未观察到任何新的安全性信号，这表明该疗法在当前试验人群中的安全性与先前认知相符。这些发现进一步支持了该疗法的整体安全性特征，为后续的研发和评估提供了重要的数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","TGTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155376428","title":"TG Therapeutics 三期增强试验证实单次600毫克Briumvi输注生物等效性","url":"https://stock-news.laohu8.com/highlight/detail?id=1155376428","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155376428?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:34","pubTimestamp":1779881660,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司公布的三期ENHANCE试验结果显示，在治疗首日单次输注600毫克Briumvi，其生物等效性得到验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","TGTX","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138241879","title":"TG Therapeutics皮下注射Briumvi三期试验顶线数据预计2026年底或2027年初公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1138241879","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138241879?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:34","pubTimestamp":1776252885,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，其皮下注射制剂Briumvi的三期临床试验顶线数据预计将于2026年底或2027年第一季度揭晓。这项关键研究旨在评估该药物在多重硬化症治疗中的安全性和有效性。\n此次数据公布将成为验证Briumvi皮下给药方案临床价值的重要里程碑。若结果积极，将为患者提供更便捷的治疗选择，并可能进一步拓展该药物的市场潜力。\n公司表示将严格遵循临床试验方案，确保数据收集的完整性和准确性。医学界正密切关注这项研究的进展，因其结果可能对多发性硬化症治疗格局产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","TGTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173950788","title":"TG Therapeutics宣布完成皮下注射Briumvi三期临床试验患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1173950788","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173950788?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:31","pubTimestamp":1776252678,"startTime":"0","endTime":"0","summary":"TG Therapeutics近日宣布，其针对皮下注射剂型Briumvi开展的三期临床试验已完成患者招募工作。这项重要进展标志着该药物在治疗多发性硬化症领域的研发迈入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173895484","title":"TG Therapeutics再获蓝猫资本5亿美元非稀释性融资 并将股票回购计划扩大至3亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173895484","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173895484?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:34","pubTimestamp":1773920044,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布从蓝猫资本获得额外5亿美元非稀释性融资，同时将现有股票回购计划规模扩大至3亿美元。这一重大资本运作将显著增强公司的财务灵活性，在保持股权结构稳定的同时为未来增长提供充足资金支持。\n通过本次融资，TG Therapeutics进一步巩固了其资金储备，为非稀释性融资模式避免了现有股东权益的摊薄。而扩大后的股票回购计划则彰显了管理层对公司长期价值的信心，有望通过优化资本结构提升股东回报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177239334","title":"异动解读 | TG Therapeutics盘中大涨5.12%，因财报亮眼并上调Briumvi收入预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1177239334","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177239334?lang=zh_cn&edition=full","pubTime":"2026-02-27 01:33","pubTimestamp":1772127204,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc.（TGTX）今日盘中股价大幅上涨5.12%，引起了市场的广泛关注。消息面上，公司披露了2025年第四季度及全年度财务业绩报告，并同时宣布上调其核心产品Briumvi的全年收入指引，这反映出该药物在市场推广和患者接纳度方面的积极进展，增强了投资者对公司未来增长潜力的信心。此次财报的公布和收入预期的上调，为投资者提供了更明确的价值锚点，可能直接推动了股价在交易时段的强劲表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192875944","title":"TG Therapeutics公布2025年第四季度及全年财报 上调Briumvi收入预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1192875944","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192875944?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:02","pubTimestamp":1772107372,"startTime":"0","endTime":"0","summary":"TG Therapeutics今日披露了2025年第四季度及全年度财务业绩报告。值得注意的是，公司同时宣布上调其核心产品Briumvi的全年收入指引，展现出对业务增长势头的强劲信心。此次调整反映了该药物在市场推广和患者接纳度方面的积极进展，为投资者提供了更明确的价值锚点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TGTX","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111244728","title":"TG Therapeutics携手克里斯蒂娜·艾伯盖特推动多发性硬化症疾病认知普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1111244728","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111244728?lang=zh_cn&edition=full","pubTime":"2026-02-09 05:18","pubTimestamp":1770585490,"startTime":"0","endTime":"0","summary":"生物制药公司TG Therapeutics近日宣布，将与知名演员克里斯蒂娜·艾伯盖特展开深度合作，共同致力于提升公众对多发性硬化症的认知水平。此次合作旨在通过名人影响力扩大疾病科普覆盖面，帮助患者群体获得更广泛的社会支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132472380","title":"TG Therapeutics公布Briumvi®（Ublituximab）多发性硬化症数据亮相美洲多发性硬化症治疗与研究委员会年度论坛","url":"https://stock-news.laohu8.com/highlight/detail?id=1132472380","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132472380?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:31","pubTimestamp":1770381080,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，其针对多发性硬化症的创新药物Briumvi®（Ublituximab）的最新临床数据，将在美洲多发性硬化症治疗与研究委员会（ACTRIMS）年度论坛上进行专题报告。此次展示将涵盖该药物的疗效持久性、安全性特征及对患者生活质量的影响等多维度研究结果，为医学界提供更全面的治疗参考依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","TGTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112173479","title":"TG Therapeutics公布Briumvi®治疗多发性硬化症数据在美洲多发性硬化症治疗与研究委员会年会上的展示日程","url":"https://stock-news.laohu8.com/highlight/detail?id=1112173479","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112173479?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:32","pubTimestamp":1769517120,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司近日宣布，其旗下药物Briumvi针对多发性硬化症的研究数据将在美洲多发性硬化症治疗与研究委员会年度论坛上进行系列展示。相关展示日程已正式确定。Briumvi作为一种创新疗法，其临床数据备受业界关注。TG Therapeutics此次公布展示安排，标志着该药物在多发性硬化症治疗领域的研究进入新阶段。公司表示，这些数据展示将涵盖Briumvi在多发性硬化症治疗中的有效性、安全性及最新临床研究成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166654438","title":"TG Therapeutics股价创去年11月以来新高，初步2025年销售额超预期，收盘大涨12.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166654438","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166654438?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:44","pubTimestamp":1768401886,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc. (TGTX) 股价今日强势攀升，收盘录得12.9%的可观涨幅，创下去年11月以来的最高水平。此番强劲表现主要得益于公司发布的初步数据显示，其2025年的销售额预期已超越市场共识。\n市场对这家生物技术公司的前景展现出浓厚兴趣，投资者情绪受到积极销售指引的显著提振。股价的飞跃反映出市场对其未来增长潜力的重新评估和坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","TGTX","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104121370","title":"TG Therapeutics盘初大涨18%，2025销售业绩超预期，2026营收指引乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1104121370","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104121370?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:34","pubTimestamp":1768401285,"startTime":"0","endTime":"0","summary":"显示出对未来增长的乐观预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133474703","title":"异动解读 | 初步销售额超预期及2026年营收指引乐观，TG Therapeutics盘前大涨7.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133474703","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133474703?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:14","pubTimestamp":1768385685,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc.（TGTX）今日盘前大涨7.18%，股价表现强劲。消息面上，公司公布的2025年初步净销售额为6.16亿美元，超出此前预期的6亿美元。同时，公司对2026年的营收指引为8.75亿至9亿美元，显示出对未来增长的乐观预期。公司首席执行官Michael Weiss表示，若多发性硬化症药物Briumvi获得批准，新的静脉输注计划有望短期内提升收入，进一步增强了市场信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178336933","title":"异动解读 | 初步销售额超预期及2026年营收指引乐观，TG Therapeutics夜盘大涨7.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178336933","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178336933?lang=zh_cn&edition=full","pubTime":"2026-01-14 16:40","pubTimestamp":1768380055,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc.（TGTX）今日夜盘大涨7.61%，股价表现强劲。消息面上，公司公布的2025年初步净销售额为6.16亿美元，超出此前预期的6亿美元。同时，公司对2026年的营收指引为8.75亿至9亿美元，显示出对未来增长的乐观预期。公司首席执行官Michael Weiss表示，若多发性硬化症药物Briumvi获得批准，新的静脉输注计划有望短期内提升收入，进一步增强了市场信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tgtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.455},{"period":"3month","weight":0.5899},{"period":"6month","weight":0.8207},{"period":"1year","weight":0.469},{"period":"ytd","weight":0.7883}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TG Therapeutics, Inc.于1993年在特拉华州注册成立。该公司是一家完全整合的、商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的收购、开发和商业化。其产品BRIUMVI（ublituximab-xiiy）已获得美国、欧盟和英国的监管批准，用于治疗复发性多发性硬化症成人患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.050204},{"month":2,"riseRate":0.692308,"avgChangeRate":0.07145},{"month":3,"riseRate":0.692308,"avgChangeRate":0.11238},{"month":4,"riseRate":0.461538,"avgChangeRate":0.020303},{"month":5,"riseRate":0.538462,"avgChangeRate":0.00629},{"month":6,"riseRate":0.571429,"avgChangeRate":0.083309},{"month":7,"riseRate":0.357143,"avgChangeRate":-0.003834},{"month":8,"riseRate":0.538462,"avgChangeRate":-0.030643},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.032476},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.061104},{"month":11,"riseRate":0.846154,"avgChangeRate":0.172847},{"month":12,"riseRate":0.461538,"avgChangeRate":0.09546}],"exchange":"NASDAQ","name":"TG Therapeutics Inc.","nameEN":"TG Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TG Therapeutics Inc.(TGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TG Therapeutics Inc.(TGTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TG Therapeutics Inc.,TGTX,TG Therapeutics Inc.股票,TG Therapeutics Inc.股票老虎,TG Therapeutics Inc.股票老虎国际,TG Therapeutics Inc.行情,TG Therapeutics Inc.股票行情,TG Therapeutics Inc.股价,TG Therapeutics Inc.股市,TG Therapeutics Inc.股票价格,TG Therapeutics Inc.股票交易,TG Therapeutics Inc.股票购买,TG Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TG Therapeutics Inc.(TGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TG Therapeutics Inc.(TGTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}